{"nctId":"NCT00957372","briefTitle":"Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy","startDateStruct":{"date":"2004-12"},"conditions":["Partial Epilepsy"],"count":253,"armGroups":[{"label":"ESL 800 mg daily (Part I)","type":"EXPERIMENTAL","interventionNames":["Drug: eslicarbazepine acetate"]},{"label":"ESL 1200 mg daily (Part I)","type":"EXPERIMENTAL","interventionNames":["Drug: eslicarbazepine acetate"]},{"label":"placebo (Part I)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo (Part I)"]},{"label":"ESL - Open-label Extension (Part II)","type":"EXPERIMENTAL","interventionNames":["Drug: ESL - Open-label Extension (Part II)"]}],"interventions":[{"name":"eslicarbazepine acetate","otherNames":["Zebinix"]},{"name":"placebo (Part I)","otherNames":[]},{"name":"ESL - Open-label Extension (Part II)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* written informed consent signed by patient\n* aged 18 years or more\n* documented diagnosis of simple or complex partial seizures with or without secondary generalisation since at least 12 months prior to screening\n* at least 4 partial seizures in each 4 week period during the last 8 weeks prior to screening, currently treated with 1 or 2 AEDs (any except oxcarbazepine and felbamate), in a stable dose regimen during at least 2 months prior to screening (patients using vigabatrin should have been on this medication for at least 1 year with no deficit in visual field identified)\n* excepting epilepsy, patient is judged to be in general good health based on medical history, physical examination and laboratory tests\n* post-menopausal or otherwise incapable of becoming pregnant by reason of surgery or tubal ligation; in case of woman of childbearing potential, patient must present a serum beta-hCG test consistent with a non-gravid state and agree to remain abstinent or use reliable contraception (oral contraception should be combined with a barrier method)\n\nExclusion Criteria:\n\n* only simple partial seizures with no motor symptomatology (classified as A2-4 according to the International Classification of Epileptic Seizures) that are not video-EEG documented\n* primarily generalised epilepsy\n* known rapid progressive neurological disorder; history of status epilepticus or cluster seizures (i.e., 3 or more seizures within 30 minutes) within the 3 months prior to screening\n* seizures of psychogenic origin within the last 2 years\n* history of schizophrenia or suicide attempt\n* currently on or with exposure to felbamate or oxcarbazepine more within one month of screening\n* using benzodiazepines on more than on an occasional basis (except when used chronically as AED)\n* previous use of ESL or participation in a clinical study with ESL\n* known hypersensitivity to carbamazepine, oxcarbazepine or chemically related substances\n* history of abuse of alcohol, drugs or medications within the last 2 years\n* uncontrolled cardiac, renal, hepatic, endocrine, gastrointestinal, metabolic, haematological or oncology disorder\n* second or third-degree atrioventricular blockade not corrected with a pacemaker\n* relevant clinical laboratory abnormalities","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Seizure Frequency","description":"The primary efficacy endpoint is the natural log transformation of the seizure frequency per 4 weeks. The primary efficacy analysis was based on results for the ITT population during the 12-week maintenance period. Seizure frequency was compared between each active treatment group and the placebo group using an ANCOVA model with treatment as a factor and seizure frequency as a covariate","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":null},{"groupId":"OG001","value":"5.7","spread":null},{"groupId":"OG002","value":"5.5","spread":null}]}]}]},{"type":"PRIMARY","title":"PART II: NÂº of Treatment-Emergent Adverse Events (TEAE)","description":"The primary objective for Part II of the study was to evaluate the safety and tolerability of eslicarbazepine acetate (ESL, BIA 2-093) at doses titrated to an efficacy or safety endpoint over a 1-year open-label period. Safety assessments were based primarily on AEs (Number of participants with at least one treatment-emergent adverse events are reported); assessment of AEs was based on treatment relatedness, action taken on study drug, outcome, and causality.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"94","spread":null},{"groupId":"OG003","value":"66","spread":null},{"groupId":"OG004","value":"9","spread":null},{"groupId":"OG005","value":"11","spread":null},{"groupId":"OG006","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":87},"commonTop":["Dizziness","Somnolence","Headache","Vomiting","Nausea"]}}}